Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
JANSSEN NZ LIMITED,Guselkumab,"First-line biologic, psoriatic arthritis where DMARDs are not effective",Guselkumab (TREMFYA),Recommended for decline,Community and Hospital,
